文献速递肺外科

IA期浸润性黏液腺癌术后生存与肿瘤学特征

Postoperative survival and oncologic characteristics of stage IA invasive mucinous adenocarcinoma.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2026-10-01

本研究回顾性分析三家机构1228例病理IA期肺腺癌(排除pT1mi)手术患者,其中浸润性黏液腺癌100例、非黏液腺癌1128例,经倾向评分匹配后比较生存。匹配后5年总生存率分别为90.4%和92.7%,5年无复发生存率分别为83.7%和93.3%,生存曲线无显著差异。结论认为病理IA期浸润性黏液腺癌术后预后与非黏液腺癌相当,黏液组织学本身不应视为早期不良预后因素。

要点

  • IA期浸润性黏液腺癌术后5年总生存率与非黏液腺癌相当。
  • 匹配后5年无复发生存率黏液组83.7%、非黏液组93.3%,差异无统计学意义。
  • 早期黏液组织学本身不应视为不良预后因素。

核心结论

  • 病理IA期浸润性黏液腺癌术后预后与非黏液腺癌相当,黏液组织学本身不应视为早期不良预后因素。

研究设计与样本

  • 回顾性研究,纳入三家机构病理IA期肺腺癌手术患者(排除pT1mi),共1228例,其中非黏液腺癌1128例、浸润性黏液腺癌100例,采用倾向评分匹配减少基线失衡。

主要发现

  • 匹配前,浸润性黏液腺癌与更小的病理全肿瘤尺寸、更大的病理浸润肿瘤尺寸及更低的淋巴血管侵犯频率显著相关。
  • 匹配前5年总生存率黏液组92.5%、非黏液组92.7%,5年无复发生存率分别为87.5%和92.3%。
  • 匹配后5年总生存率黏液组90.4%、非黏液组92.7%,5年无复发生存率分别为83.7%和93.3%,两组生存曲线无显著差异。

临床怎么用

  • 对于病理IA期浸润性黏液腺癌,术后预后评估可参照非黏液腺癌,不必仅因黏液组织学而升级为不良预后因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The prognosis of invasive mucinous adenocarcinoma has not been well investigated because of its rarity, especially with regard to early-stage disease. This study aimed to compare the prognosis of early-stage invasive mucinous adenocarcinoma with that of non-mucinous adenocarcinoma and to clarify oncologic characteristics of early-stage invasive mucinous adenocarcinoma. METHODS: Patients with pathological stage IA lung adenocarcinoma, excluding pT1mi tumors, who underwent surgery at three institutions were retrospectively examined. Overall survival and recurrence-free survival were compared between patients with invasive mucinous adenocarcinoma and non-mucinous adenocarcinoma. Propensity score matching was applied to reduce baseline imbalances. RESULTS: Among the 1228 patients, 1128 had non-mucinous adenocarcinoma and 100 had invasive mucinous adenocarcinoma. Before matching, invasive mucinous adenocarcinoma was significantly associated with smaller pathological whole tumor size, larger pathological invasive tumor size and a lower frequency of lymphovascular invasion. The 5-year overall survival rates were 92.5% and 92.7%, and the 5-year recurrence-free survival rates were 87.5% and 92.3% in patients with invasive mucinous and non-mucinous adenocarcinoma, respectively. Baseline covariates including pathological tumor size and stage were generally balanced after matching. The 5-year overall survival rates were 90.4% and 92.7%, and the 5-year recurrence-free survival rates were 83.7% and 93.3%, respectively, with no significant differences in survival curves between groups. CONCLUSIONS: The postoperative prognosis of patients with pathological stage IA invasive mucinous adenocarcinoma was comparable to that of patients with non-mucinous adenocarcinoma. These findings suggest that mucinous histology alone should not be considered an adverse prognostic factor in early-stage disease.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Ueda D, Mimae T, Kudo Y, et al. Postoperative survival and oncologic characteristics of stage IA invasive mucinous adenocarcinoma. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42820784. doi:10.1093/icvts/ivag272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。